SMARCA4 and adenocarcinoma: Histologically, 21 patients (58.3%) were diagnosed with SMARCA4‐NSCLCs, which included 15 NSCLCs not otherwise specified (41.7%), 4 adenocarcinomas (11.1%), 1 squamous cell carcinoma (2.8%) and 1 adenosquamous carcinoma (2.8%).